Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, Safety, and Immunogenicity of CT-P6 vs Herceptin in Healthy Subjects
NCT02665637Phase 1Completed
- Sponsor
- Celltrion
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in breast cancer and gastric cancer (GC) (2 arms), sponsored by Celltrion. Primary endpoint: Area Under the Curve at 10 weeks. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02665637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665637.